Statistics from Altmetric.com
In their review, Frazer and Martin1 address imbalanced supply with arachidonic (ARA) and docosahexaenoic acid (DHA) as central to preterm infant parenteral nutrition, advocating administration in adequate amounts and ratios, that fish oil containing suspensions corrupt physiological fatty acid profile and that supplying DHA without ARA is harmful to preterm infants <29 weeks. At 4 g/kg/d fat supply, SMOFlipid (2–7 mg/mL DHA) delivers 40–140 mg/kg/d DHA, but <10 mg/kg/d ARA (own unpublished data), contrasting with ~140–212 mg/kg/d ARA and ~43 mg/kg/d DHA physiological accretion during the third trimester. While we fully agree, additional aspects should be taken into account:
The authors suggest an ARA:DHA ratio of 2:1, which was associated with superior outcome when compared with lower …
Contributors This letter’s first draft has been written by WB and was then extensively discussed and approved by all three authors.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.